Evidence map›Paper›PMID 38318187›Full record

ArticleFrontiers in immunology2024

Soluble CD147 regulates endostatin via its effects on the activities of MMP-9 and secreted proteasome 20S.

Maya M Rahat, Hala Sabtan, Elina Simanovich, Amir Haddad, Tal Gazitt, Joy Feld, Gleb Slobodin, Adi Kibari, Muna Elias, Devy Zisman and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Tofacitinib Regulates Endostatin via Effects on CD147 and Cathepsin S.International journal of molecular sciences · 2024
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Maya M RahatImmunotherapy Laboratory, Carmel Medical Center, Haifa, Israel.
Hala SabtanImmunotherapy Laboratory, Carmel Medical Center, Haifa, Israel.
Elina SimanovichImmunotherapy Laboratory, Carmel Medical Center, Haifa, Israel.
Amir HaddadDepartment of Rheumatology, Carmel Medical Center, Haifa, Israel.
Tal GazittDepartment of Rheumatology, Carmel Medical Center, Haifa, Israel.
Joy FeldDepartment of Rheumatology, Carmel Medical Center, Haifa, Israel.
Gleb SlobodinThe Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Adi KibariDepartment of Rheumatology, Carmel Medical Center, Haifa, Israel.
Muna EliasDepartment of Rheumatology, Carmel Medical Center, Haifa, Israel.
Devy ZismanDepartment of Rheumatology, Carmel Medical Center, Haifa, Israel.
Michal A RahatImmunotherapy Laboratory, Carmel Medical Center, Haifa, Israel.
Technion – Israel Institute of Technology · ILCarmel Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During progression of rheumatoid arthritis (RA), angiogenesis provides oxygen and nutrients for the cells' increased metabolic demands and number. To turn on angiogenesis, pro-angiogenic factors must outweigh anti-angiogenic factors. We have previously shown that CD147/extracellular matrix metalloproteinase inducer (EMMPRIN) can induce the expression of the pro-angiogenic factors vascular endothelial growth factor (VEGF) and matrix metallopeptidase 9 (MMP-9) in a co-culture of the human HT1080 fibrosarcoma and U937 monocytic-like cell lines. However, whether CD147 influences anti-angiogenic factors was not known. We now show that relative to single cultures, the co-culture of these cells not only enhanced pro-angiogenic factors but also decreased the anti-angiogenic factors endostatin and thrombospondin-1 (Tsp-1), generally increasing the angiogenic potential as measured by a wound assay. Using anti-CD147 antibody, CD147 small interfering RNA (siRNA), and recombinant CD147, we demonstrate that CD147 hormetically regulates the generation of endostatin but has no effect on Tsp-1. Since endostatin is cleaved from collagen XVIII (Col18A), we applied different protease inhibitors and established that MMP-9 and proteasome 20S, but not cathepsins, are responsible for endostatin generation. MMP-9 and proteasome 20S collaborate to synergistically enhance endostatin generation, and in a non-cellular system, CD147 enhanced MMP-9 activity and hormetically regulated proteasome 20S activity. Serum samples obtained from RA patients and healthy controls mostly corroborated these findings, indicating clinical relevance. Cumulatively, these findings suggest that secreted CD147 mediates a possibly allosteric effect on MMP-9 and proteasome 20S activities and can serve as a switch that turns angiogenesis on or off, depending on its ambient concentrations in the microenvironment.

Indexed as

Arthritis, RheumatoidBasiginEndostatinsHumansMatrix Metalloproteinase 9Matrix Metalloproteinase InhibitorsProteasome Endopeptidase ComplexThrombospondin 1Vascular Endothelial Growth Factor ABasiginBSG protein, humanEndostatinsMatrix Metalloproteinase 9Matrix Metalloproteinase InhibitorsProteasome Endopeptidase ComplexThrombospondin 1Vascular Endothelial Growth Factor AangiogenesisCD147/EMMPRINendostatinfibroblasts-monocytes interactionsMMP-9secreted proteasome 20S

Identifiers

PMID38318187
PMCPMC10840997
OpenAlexW4391111409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.